Muscle-Specific Expression Cassettes for Tunable Gene Therapy Output
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapy technologies struggle to achieve uniform and optimal expression of therapeutic proteins in skeletal and cardiac muscle cells while minimizing expression in non-muscle cells, leading to suboptimal or toxic levels due to variable transduction efficiencies and fiber type differences.
Innovation Solution
Development of Muscle-Specific Expression Cassettes (MSECs) that selectively express coding sequences in skeletal and cardiac muscle cells, with varying expression levels over a broad range, using modified muscle-specific gene regulatory components and microRNA target sites to control product levels, ensuring minimal expression in non-muscle cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional gene therapy technologies are used to express therapeutic proteins in muscle cells, then some expression is achieved, but the expression levels are variable and non-uniform due to transduction efficiencies and fiber type differences
Solution Approach 1:
The patent applies local quality by designing fiber type-specific regulatory cassettes that differentially regulate gene expression in slow-twitch versus fast-twitch muscle fibers. The regulatory cassettes contain fiber type-specific enhancers and promoters that are activated only in specific fiber types, ensuring uniform and optimal expression levels tailored to each fiber type's characteristics rather than attempting uniform expression across all fiber types.
Solution Approach 2:
The patent changes the regulatory parameters of gene expression by using microRNA target sites and fiber type-specific transcriptional regulators. By incorporating multiple microRNA binding sites with different affinities and using fiber type-specific promoters, the system dynamically adjusts expression levels to achieve uniform therapeutic protein production across diverse muscle fiber types despite variable transduction efficiencies.
2Productivity
If high expression levels are achieved in muscle cells, then therapeutic benefit is increased, but toxicity may occur from excessive expression
Solution Approach 1:
The patent applies dynamics by creating a tunable and adjustable expression system using regulatory cassettes with microRNA target sites. The expression levels can be dynamically adjusted by modifying the number and affinity of microRNA binding sites, allowing the system to achieve optimal therapeutic levels without exceeding toxicity thresholds. This dynamic control enables fine-tuning of expression based on therapeutic needs while preventing harmful overexpression.
Solution Approach 2:
The patent implements feedback control through microRNA-mediated regulation. The regulatory cassettes include microRNA target sites that respond to cellular conditions and feedback mechanisms to maintain expression within safe therapeutic ranges. When expression levels become excessive, the microRNA system provides negative feedback to reduce transcription, preventing toxicity while maintaining sufficient therapeutic benefit.
3Area of stationary object
If gene therapy is delivered systemically, then broad muscle coverage is achieved, but non-muscle cells may also be transduced leading to unwanted expression
Solution Approach 1:
The patent converts the potential harm of ubiquitous promoter activity into a benefit by using it for high-level muscle expression while adding fiber type-specific regulatory elements. The ubiquitous promoter ensures broad muscle coverage and strong expression, while the incorporated fiber type-specific enhancers and microRNA target sites selectively restrict functional expression to the intended muscle fiber types, preventing unwanted expression in non-muscle cells.
4Manufacturing precision
If fiber type-specific expression is implemented, then optimal expression in target fibers is achieved, but the device complexity increases due to multiple regulatory components
Solution Approach 1:
The patent applies segmentation by dividing the regulatory cassette into distinct functional modules: fiber type-specific enhancers, promoters, microRNA target sites, and transcriptional regulators. Each module performs a specific function in controlling fiber type-specific expression. This modular segmentation allows for systematic design and optimization of expression control while maintaining manageable complexity through organized functional units.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A library of artificial muscle-specific expression cassettes (MSECs) for muscle-specific gene expression is described. Different members of the library can be selected for varied transcription levels in different muscle cell types, for different research or therapeutic purposes. MSECs within the library can be used to develop treatments for muscle-related disorders.